Last updated on November 2019

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Brief description of study

To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia

Clinical Study Identifier: NCT03121586

Find a site near you

Start Over

MUDr. Tibor Miklos

Praha 10, Czechia
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.